Incyte Corporation (INCY)
| Market Cap | 24.66B +16.1% |
| Revenue (ttm) | 6.01B +24.9% |
| Net Income | 403.41M -66.1% |
| EPS | 1.94 -67.1% |
| Shares Out | 203.83M |
| PE Ratio | 62.23 |
| Forward PE | 15.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 950,394 |
| Open | 121.89 |
| Previous Close | 121.70 |
| Day's Range | 119.72 - 122.07 |
| 52-Week Range | 89.25 - 132.60 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 131.50 (+8.71%) |
| Earnings Date | Oct 29, 2026 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $131.5, which is an increase of 8.71% from the latest price.
News
Incyte will not proceed with planned Phase 3 MAESTRA-3 study of INCB123667
Incyte (INCY) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenan...
Natera announces clinical collaboration with Incyte
Natera (NTRA) announced that it has entered into a clinical collaboration agreement with Incyte (INCY) for a new phase II study in colorectal cancer, CRC. The trial will evaluate INCA33890,…
Incyte Transcript: 8th Annual Wolfe Research Healthcare Conference
The ex-JAKAFI core grew >30% YoY in Q3, while management targets $3B-$4B by 2030 and top-quartile growth post-2029. Near-term catalysts include povorcitinib and XR launches, CALR data and advancing G12D and TGF-beta programs.
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with In...
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipi...
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH26--Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026.
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Wolfe Research Healthcare Conference on...
Incyte price target raised to $108 from $104 at Bernstein
Bernstein raised the firm’s price target on Incyte (INCY) to $108 from $104 and keeps a Market Perform rating on the shares. All in, the firm says it is encouraging…
Incyte price target lowered to $116 from $119 at Morgan Stanley
Morgan Stanley analyst Chris Yu lowered the firm’s price target on Incyte (INCY) to $116 from $119 and keeps an Equal Weight rating on the shares. Incyte posted a Q3…
Incyte price target raised to $127 from $125 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Incyte (INCY) to $127 from $125 and keeps an In Line rating on the shares.
Incyte price target lowered to $127 from $128 at Wells Fargo
Wells Fargo lowered the firm’s price target on Incyte (INCY) to $127 from $128 and keeps an Equal Weight rating on the shares. The firm thought the Q3 update was…
Incyte price target raised to $143 from $139 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Incyte (INCY) to $143 from $139 and keeps an Overweight rating on the shares.
Oppenheimer upgrades Incyte on growth outside of Jakafi
Oppenheimer last night upgraded Incyte (INCY) to Outperform from Perform with a price target of $144, up from $120. The company is “increasingly demonstrating a credible path to growth” beyond…
Incyte upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Jay Olson upgraded Incyte (INCY) to Outperform from Perform with a price target of $144, up from $120.
Incyte Earnings Call Transcript: Q3 2026
Q3 revenue and net sales rose 14% YoY, and FY2026 net sales guidance increased. OPZELURA and hematology/oncology growth brands drove results as late-stage pipeline programs advanced.
Incyte Earnings release: Q3 2026
Incyte released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Incyte Slides: Q3 2026
Incyte has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Incyte Quarterly report: Q3 2026
Incyte has published its Q3 2026 quarterly earnings report on October 29, 2026.
Incyte reports Q3 EPS ($3.60), consensus ($4.25)
Reports Q3 revenue $1.56B, consensus $1.46B. “Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements,” said Bill Meury, Chief...
Incyte raises FY26 revenue view to $5.21B-$5.3B from $5.13B-$5.26B
Consensus $5.92B
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.
Incyte Transcript: Investor update
'890 plus FOLFOX-bev showed a 71% response rate and 81% six-month PFS in first-line MSS colorectal cancer. '734 showed encouraging activity in pancreatic and later-line colorectal cancer, supporting ongoing and planned pivotal trials.
Incyte Press release: Investor update
Incyte issued a press release on October 26, 2026, disclosing material business information to investors.
Incyte Slides: Investor update
Incyte has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Incyte highlights data across gastrointestinal cancer portfolio at ESMO 2026
Incyte (INCY) announced new results from its advancing oncology portfolio, including updated results for its KRAS G12D inhibitor in pancreatic ductal adenocarcinoma and advanced or metastatic colorect...